Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication February 17, 2015
- Accepted for publication March 23, 2015
- Published online June 1, 2015.
Article Versions
- previous version (April 16, 2015 - 06:57).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Author Information
- Ken Herrmann*,1,2,
- Christina Bluemel*,1,
- Martina Weineisen3,
- Margret Schottelius3,
- Hans-Jürgen Wester3,4,
- Johannes Czernin2,
- Uta Eberlein1,
- Seval Beykan1,
- Constantin Lapa1,
- Hubertus Riedmiller5,
- Markus Krebs5,
- Saskia Kropf4,
- Andreas Schirbel1,
- Andreas K. Buck1 and
- Michael Lassmann1
- 1Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany
- 2Ahmanson Translational Imaging Division, David Geffen School of Medicine at UCLA, Los Angeles, California
- 3Pharmaceutical Radiochemistry, Technische Universität München, Munich, Germany
- 4Scintomics GmbH, Fürstenfeldbruck, Germany; and
- 5Department of Urology, University Hospital Würzburg, Würzburg, Germany
- For correspondence or reprints contact: Ken Herrmann, Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacher Strasse 6, 97080 Würzburg, Germany. E-mail:Herrmann_K1{at}ukw.de
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- Delayed Imaging Improves Lesion Detectability in [99mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer
- Matched-Pair Comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions
- Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
- Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with 67Cu
- Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer
- Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of a Novel Radiohybrid PSMA, 18F-rhPSMA-7, in Patients with Prostate Cancer
- Impact of 18F-PSMA-1007 Uptake in Prostate Cancer Using Different Peptide Concentrations: Preclinical PET/CT Study on Mice
- First Clinicopathologic Evidence of a Non-PSMA-Related Uptake Mechanism for 68Ga-PSMA-11 in Salivary Glands
- Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer
- Seduction by Sensitivity: Reality, Illusion, or Delusion? The Challenge of Assessing Outcomes after PSMA Imaging Selection of Patients for Treatment
- Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer
- 18F-DCFPyL PET/CT in the Detection of Prostate Cancer at 60 and 120 Minutes: Detection Rate, Image Quality, Activity Kinetics, and Biodistribution
- Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers
- The Clinical Impact of Additional Late PET/CT Imaging with 68Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer
- Safety, Dosimetry, and Tumor Detection Ability of 68Ga-NOTA-AE105: First-in-Human Study of a Novel Radioligand for uPAR PET Imaging
- 68Ga-PSMA Ligand PET/CT-based Radiotherapy for Lymph Node Relapse of Prostate Cancer After Primary Therapy Delays Initiation of Systemic Therapy
- Evaluation of 68Ga-Glutamate Carboxypeptidase II Ligand Positron Emission Tomography for Clinical Molecular Imaging of Atherosclerotic Plaque Neovascularization
- The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer
- 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
- New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy
- The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions